WeTrials
Recruiting

A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis

What is this study?

This study is testing a new injectable medicine called survodutide to see if it can improve liver health in adults with a serious fatty liver disease called MASH. Researchers want to find out if this medicine can help heal liver scarring and stop the disease from getting worse.

Who can participate?

You may be able to join if you are 18 or older, have stable liver scarring due to MASH, and meet specific body weight (BMI) requirements. People with heavy alcohol use or severe liver complications cannot take part.

What will happen?

You will take either the study medicine or a placebo as a weekly injection under your skin, along with healthy lifestyle counseling. The study lasts for up to four and a half years with regular check-ins, health tests, and questionnaires.

Where and when?

This study is currently recruiting participants and has locations in cities across Arizona, United States. Visits will happen at the study site or via video call.

Key Points
  • 1Testing an investigational weekly injection called survodutide for fatty liver disease
  • 2Includes guidance on healthy diet and regular exercise for all participants
  • 3Long-term study lasting up to four and a half years with regular health check-ups

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Metabolic Dysfunction Associated Steatohepatitis

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.